List of Astepro drug patents

Astepro is owned by Mylan Speciality Lp.

Astepro contains Azelastine Hydrochloride.

Astepro has a total of 3 drug patents out of which 0 drug patents have expired.

Astepro was authorised for market use on 15 October, 2008.

Astepro is available in spray, metered;nasal dosage forms.

Astepro can be used as treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis.

The generics of Astepro are possible to be released after 04 June, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof
Nov, 2025

(2 years from now)

US9919050 MYLAN SPECIALITY LP Compositions comprising azelastine
Nov, 2025

(2 years from now)

US8071073 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof
Jun, 2028

(5 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2008

Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of ASTEPRO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic